SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Papatheodoridis G.)
 

Search: WFRF:(Papatheodoridis G.) > (2023) > Machine learning al...

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

Lee, Jenny (author)
Amsterdam UMC, Netherlands
Westphal, Max (author)
Fraunhofer Inst Digital Med MEVIS, Germany
Vali, Yasaman (author)
Amsterdam UMC, Netherlands
show more...
Boursier, Jerome (author)
Angers Univ Hosp, France
Petta, Salvatorre (author)
Univ Palermo, Italy
Ostroff, Rachel (author)
SomaLogic Inc, CO USA
Alexander, Leigh (author)
SomaLogic Inc, CO USA
Chen, Yu (author)
Eli Lilly & Co Ltd LLY, IN USA
Fournier, Celine (author)
Echosens, France
Geier, Andreas (author)
Wurzburg Univ Hosp, Germany
Francque, Sven (author)
Univ Antwerp, Belgium
Wonders, Kristy (author)
Newcastle Univ, England
Tiniakos, Dina (author)
Newcastle Univ, England; Natl & Kapodistrian Univ Athens, Greece
Bedossa, Pierre (author)
Newcastle Univ, England
Allison, Mike (author)
Cambridge Univ NHS Fdn Trust, England
Papatheodoridis, Georgios (author)
Natl & Kapodistrian Univ Athens, Greece
Cortez-Pinto, Helena (author)
Univ Lisbon, Portugal
Pais, Raluca (author)
Sorbonne Univ, France
Dufour, Jean-Francois (author)
Univ Bern, Switzerland
Leeming, Diana Julie (author)
Nordic Biosci AS, Denmark
Harrison, Stephen (author)
John Radcliffe Hosp, England
Cobbold, Jeremy (author)
John Radcliffe Hosp, England
Holleboom, Adriaan G. (author)
Amsterdam Univ Med Ctr, Netherlands
Yki-Jarvinen, Hannele (author)
Univ Helsinki, Finland; Helsinki Univ Hosp, Finland; Minerva Fdn, Finland
Crespo, Javier (author)
Univ Hosp Marques Valdecilla, Spain
Ekstedt, Mattias (author)
Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
Aithal, Guruprasad P. (author)
Nottingham Univ Hosp NHS Trust, England; Univ Nottingham, England
Bugianesi, Elisabetta (author)
Univ Turin, Italy
Romero-Gomez, Manuel (author)
Univ Seville, Spain
Torstenson, Richard (author)
AstraZeneca, Sweden
Karsdal, Morten (author)
Nordic Biosci AS, Denmark
Yunis, Carla (author)
Pfizer Inc, NY USA
Schattenberg, Joern M. (author)
Univ Med Ctr Mainz, Germany
Schuppan, Detlef (author)
Univ Med Ctr Mainz, Germany; Univ Med Ctr Mainz, Germany; Harvard Med Sch, MA USA
Ratziu, Vlad (author)
Sorbonne Univ, France
Brass, Clifford (author)
Novartis Pharmaceut, NJ USA
Duffin, Kevin (author)
Eli Lilly & Co Ltd LLY, IN USA
Zwinderman, Koos (author)
Amsterdam UMC, Netherlands
Pavlides, Michael (author)
Univ Oxford, England
Anstee, Quentin M. (author)
Univ Antwerp, Belgium; Newcastle Upon Tyne Hosp NHS Trust, England
Bossuyt, Patrick M. (author)
Amsterdam UMC, Netherlands
show less...
 (creator_code:org_t)
LIPPINCOTT WILLIAMS & WILKINS, 2023
2023
English.
In: Hepatology. - : LIPPINCOTT WILLIAMS & WILKINS. - 0270-9139 .- 1527-3350. ; 78:1, s. 258-271
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background and Aims: Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F >= 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD. Approach and Results: Learning data were collected in the Liver Investigation: Testing Marker Utility in Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH CRN. Conditions of interest were the clinical trial definition of NASH (NAS >= 4;53%), at-risk NASH (NASH with F >= 2;35%), significant (F >= 2;47%), and advanced fibrosis (F >= 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputations. Data were randomly split into training/validation (75/25) sets. A gradient boosting machine was applied to develop 2 models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models.Clinical gradient boosting machine models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82). Conclusions: Detection of NASH and at-risk NASH can be improved by constructing independent machine learning models for each component, using only clinical predictors. Adding biomarkers only improved the accuracy of fibrosis.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Hepatology (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view